Evidence map›Paper›PMID 35118474›Full record

ArticlebioRxiv : the preprint server for biology2022

Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine.

Dapeng Li, David R Martinez, Alexandra Schäfer, Haiyan Chen, Maggie Barr, Laura L Sutherland, Esther Lee, Robert Parks, Dieter Mielke, Whitney Edwards and 34 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 15 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

44 authors at 9 institutions in 1 country.

Dapeng LiDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
David R MartinezDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Alexandra SchäferDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Haiyan ChenDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Maggie BarrDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Laura L SutherlandDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Esther LeeDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Robert ParksDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Dieter MielkeDepartment of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
Whitney EdwardsDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Amanda NewmanDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Kevin W BockInfectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
Mahnaz MinaiInfectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
Bianca M NagataInfectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
Matthew GagneVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
Daniel C DouekVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
C Todd DeMarcoDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Thomas N DennyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Thomas H OguinDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Alecia BrownDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Wes RountreeDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Yunfei WangDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Katayoun MansouriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Robert J EdwardsDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Guido FerrariDepartment of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
Gregory D SempowskiDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Amanda EatonDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Juanjie TangDivision of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, Silver Spring, MD 20871, USA.
Derek W CainDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Sampa SantraBeth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Norbert PardiDepartment of Microbiology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Drew WeissmanDepartment of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Mark A TomaiCorporate Research Materials Lab, 3M Company, St Paul, MN 55144, USA.
Christopher B FoxInfectious Disease Research Institute, Seattle, WA 98104, USA.
Ian N MooreInfectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
Hanne AndersenBIOQUAL, Rockville, MD 20850, USA.
Mark G LewisBIOQUAL, Rockville, MD 20850, USA.
Hana GoldingDivision of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, Silver Spring, MD 20871, USA.
Robert SederVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
Surender KhuranaDivision of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, Silver Spring, MD 20871, USA.
Ralph S BaricDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
David C MontefioriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Kevin O SaundersDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Barton F HaynesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Duke University · USNational Institutes of Health · USCenter for Biologics Evaluation and Research · USUniversity of North Carolina at Chapel Hill · USBioqual · USUniversity of Pennsylvania · US3M (United States) · USBeth Israel Deaconess Medical Center · USInfectious Disease Research Institute · US

Funding

Project 4: Computational panbetaCoV immunogen designP01AI158571 · NIAID · DUKE UNIVERSITY · PI HENDERSON, RORY · 2021 to 2023
$28.0M
Project 2 - GMP Manufacturing of mRNA ImmunogensU19AI142596 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2019 to 2024
$19.0M
Regional Biocontainment Laboratory (RBL)UC6AI058607 · NIAID · DUKE UNIVERSITY · PI WILLIAMS, R SANDERS · 2003 to 2005
$16.3M
Regional Biocontainment Laboratories Facility and Building System Upgrades SupportG20AI167200 · NIAID · DUKE UNIVERSITY · PI STAATS, HERMAN F · 2021 to 2022
$6.6M
COVID Support from the IDPS to NIAID InvestigatorsZICAI001301 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ELKINS, WILLIAM · 2020 to 2023
$168k
NIAID NIH HHS G20 AI167200NIAID NIH HHS P01 AI158571NIAID NIH HHS U19 AI142596NIAID NIH HHS UC6 AI058607
6 · The paper itself

Abstract

Coronavirus vaccines that are highly effective against SARS-CoV-2 variants are needed to control the current pandemic. We previously reported a receptor-binding domain (RBD) sortase A-conjugated ferritin nanoparticle (RBD-scNP) vaccine that induced neutralizing antibodies against SARS-CoV-2 and pre-emergent sarbecoviruses and protected monkeys from SARS-CoV-2 WA-1 infection. Here, we demonstrate SARS-CoV-2 RBD-scNP immunization induces potent neutralizing antibodies in non-human primates (NHPs) against all eight SARS-CoV-2 variants tested including the Beta, Delta, and Omicron variants. The Omicron variant was neutralized by RBD-scNP-induced serum antibodies with a mean of 10.6-fold reduction of ID50 titers compared to SARS-CoV-2 D614G. Immunization with RBD-scNPs protected NHPs from SARS-CoV-2 WA-1, Beta, and Delta variant challenge, and protected mice from challenges of SARS-CoV-2 Beta variant and two other heterologous sarbecoviruses. These results demonstrate the ability of RBD-scNPs to induce broad neutralization of SARS-CoV-2 variants and to protect NHPs and mice from multiple different SARS-related viruses. Such a vaccine could provide the needed immunity to slow the spread of and reduce disease caused by SARS-CoV-2 variants such as Delta and Omicron.

Identifiers

PMID35118474
PMCPMC8811946
OpenAlexW4210371513

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.